have been evolutionarily selected to bind to biological macromolecules and, thus, represent “privileged structures” which are excellent templates for the synthesis of novel, biologically active, natural product-like molecules. Of course, suitable biological assays for evaluation of the structure-activity relationships (SARs) of the optimization products are required for all these approaches, and thus, a truly multidisciplinary, collaborative approach is required for
effective natural product-based drug discovery and development.